# Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

> **NCT02743611** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bellicum Pharmaceuticals** · enrollment: 4 (actual)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Uveal Melanoma

## Interventions

- **BIOLOGICAL:** BPX-701
- **DRUG:** Rimiducid

## Key facts

- **NCT ID:** NCT02743611
- **Lead sponsor:** Bellicum Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-14
- **Primary completion:** 2019-07-19
- **Final completion:** 2020-07-19
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** company decision
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02743611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02743611, "Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02743611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*